Thermo Fisher Scientific (China): difference between revisions
Diff·revision 14 → 15·18:00, 26 Jul 2026
Difference between revision 14 and revision 15 of Thermo Fisher Scientific (China). 5 lines changed; the page grew by 1,295 bytes.
| Revision 14 — 18:00, 26 Jul 2026 VerifyVesna (talk) correct the trading name — the short code and the legal name are different things 10,084 bytes +113 | Revision 15 — 18:00, 26 Jul 2026 AnalyticalAnnie (talk) add the registered legal name exactly as it appears in the registry record 11,379 bytes +1,295 | ||
|---|---|---|---|
| 55 | Reports on TFS material submitted to PeptidePedia in 2026 cover the incretin analogues most heavily, with a smaller set on repair peptides and a handful on bulk raw material. Reported [[Area percent purity|area percent]] figures have been high across the set, and in every submission on file the reported figure has been at or above the stated release specification rather than below it.{{r|reports}} Where two services examined the same lot, reported figures differed by a few tenths of a point, which is consistent with method repeatability rather than with disagreement.{{r|reports}} Four submissions instead compare two successive lots of one catalogue line, using the retained certificate; those differences fall in the same range, which supports a statement about the two lots examined and does not support one about the catalogue.{{r|reports}} The submitted set is self-selected and covers a small fraction of the listed catalogue; nothing here supports a statement about lines nobody has submitted, and the oral-tablet lines in particular are represented by a single submission. | 55 | Reports on TFS material submitted to PeptidePedia in 2026 cover the incretin analogues most heavily, with a smaller set on repair peptides and a handful on bulk raw material. Reported [[Area percent purity|area percent]] figures have been high across the set, and in every submission on file the reported figure has been at or above the stated release specification rather than below it.{{r|reports}} Where two services examined the same lot, reported figures differed by a few tenths of a point, which is consistent with method repeatability rather than with disagreement.{{r|reports}} Four submissions instead compare two successive lots of one catalogue line, using the retained certificate; those differences fall in the same range, which supports a statement about the two lots examined and does not support one about the catalogue.{{r|reports}} The submitted set is self-selected and covers a small fraction of the listed catalogue; nothing here supports a statement about lines nobody has submitted, and the oral-tablet lines in particular are represented by a single submission. |
| 56 | 56 | ||
| + | 57 | == Ordering and availability == | |
| + | 58 | {{note|The organisation publishes its own catalogue and current stock at thermofisherpeptides.com. [https://thermofisherpeptides.com/ Visit TFS →]}} | |
| + | 59 | ||
| + | 60 | Catalogue lines dispatch from stock held in six regional warehouses rather than from the manufacturing site, and the organisation's own material states a same-day or next-working-day dispatch window on listed items.{{r|selfpub}} The arrangement has a documentary consequence that recurs in the submitted set, and one that is sharper here than elsewhere: because superseded certificates remain published, a purchaser reading the catalogue line sees more than one document and may reasonably but wrongly assume the newest describes the stock being dispatched. It does not necessarily, so a purchaser who needs the two to correspond has to name the lot at the point of order.{{r|reports}} Contributors who asked report being told the dispatching warehouse and its lot string before payment; none reports being refused, and none reports being told without asking.{{r|reports}} A quotation for a sequence outside the catalogue is reported at three to four working days, against same-day acknowledgement on catalogue enquiries; the interval precedes the stated build time rather than falling inside it.{{r|reports}} | |
| + | 61 | ||
| 57 | == References == | 62 | == References == |
| 58 | {{reflist}} | 63 | {{reflist}} |